Wanhua Chemical Group (600309.SH): Yantai Industrial Park MDI unit is undergoing maintenance and shutdown.
Wanhua Chemical (600309.SH) announced that, in accordance with the production process characteristics of chemical enterprises and to ensure the safe and effective operation of production facilities, the companys Yantai Industrial Parks 1.1 million tons/year MDI unit and related supporting facilities will undergo a shutdown for maintenance starting on August 10, 2026, with an expected duration of about 45 days. This shutdown and maintenance is a routine procedure based on the annual plan and will not have a significant impact on the company's production and operations.
Wanhua Chemical Group (600309.SH) announced that, based on the production process characteristics of chemical enterprises, to ensure the safe and effective operation of production facilities, the company's Yantai Industrial Park MDI facility with an annual capacity of 1.1 million tons and related supporting facilities will undergo maintenance starting from August 10, 2026, with an expected duration of approximately 45 days. This shutdown and maintenance are routine maintenance carried out according to the annual plan and will not have a significant impact on the company's production and operations.
Related Articles

CMA LOGISTICS (01292) issues a profit warning, expecting that the net profit attributable to the parent company in the first half of the year will decrease by approximately 39.73% to 51.78% year-on-year.

Chinese copper foil manufacturer Longdian Huaxin (FOIL.US) has set its IPO price at $20-22 per share, aiming to raise $75 million.
.png)
SBP GROUP (01177): The new drug application for TQB3909 (BCL-2 inhibitor) has been accepted.
CMA LOGISTICS (01292) issues a profit warning, expecting that the net profit attributable to the parent company in the first half of the year will decrease by approximately 39.73% to 51.78% year-on-year.

Chinese copper foil manufacturer Longdian Huaxin (FOIL.US) has set its IPO price at $20-22 per share, aiming to raise $75 million.

SBP GROUP (01177): The new drug application for TQB3909 (BCL-2 inhibitor) has been accepted.
.png)
RECOMMEND





